Immunovant
IMVT
IMVT
186 hedge funds and large institutions have $2.04B invested in Immunovant in 2024 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 67 increasing their positions, 61 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
10% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 61
9% less capital invested
Capital invested by funds: $2.24B → $2.04B (-$204M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Holders
186
Holding in Top 10
6
Calls
$73.9M
Puts
$18.2M
Top Buyers
| 1 | +$60.3M | |
| 2 | +$44.2M | |
| 3 | +$40.9M | |
| 4 |
JPMorgan Chase & Co
New York
|
+$22.9M |
| 5 |
TSC
Two Seas Capital
Rye,
New York
|
+$20.7M |
Top Sellers
| 1 | -$38.9M | |
| 2 | -$27.8M | |
| 3 | -$22.6M | |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$19.8M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$19.1M |